Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1960 1
1961 1
1982 2
1983 5
1984 7
1985 2
1986 7
1987 5
1988 8
1989 4
1990 9
1991 13
1992 12
1993 14
1994 24
1995 39
1996 53
1997 116
1998 178
1999 210
2000 313
2001 323
2002 392
2003 517
2004 588
2005 708
2006 767
2007 992
2008 861
2009 858
2010 892
2011 796
2012 750
2013 656
2014 618
2015 540
2016 471
2017 445
2018 204
2019 71
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

11,238 results
Results by year
Filters applied: . Clear all
Page 1
Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Nanjan MJ, et al. Bioorg Chem. 2018 Apr;77:548-567. doi: 10.1016/j.bioorg.2018.02.009. Epub 2018 Feb 12. Bioorg Chem. 2018. PMID: 29475164 Review.
The role of CD36 receptor in the pathogenesis of atherosclerosis.
Choromańska B, Myśliwiec P, Choromańska K, Dadan J, Chabowski A. Choromańska B, et al. Adv Clin Exp Med. 2017 Jul;26(4):717-722. doi: 10.17219/acem/62325. Adv Clin Exp Med. 2017. PMID: 28691408 Free article. Review.
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R. Molinaro E, et al. Nat Rev Endocrinol. 2017 Nov;13(11):644-660. doi: 10.1038/nrendo.2017.76. Epub 2017 Jul 14. Nat Rev Endocrinol. 2017. PMID: 28707679 Review.
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. Botta M, et al. Int J Mol Sci. 2018 Apr 14;19(4):1197. doi: 10.3390/ijms19041197. Int J Mol Sci. 2018. PMID: 29662003 Free PMC article. Review.
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Ahrén B, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3. Lancet Diabetes Endocrinol. 2017. PMID: 28385659 Clinical Trial.
Non-insulin pharmacological therapies for treating type 1 diabetes.
Frandsen CS, Dejgaard TF, Madsbad S, Holst JJ. Frandsen CS, et al. Expert Opin Pharmacother. 2018 Jun;19(9):947-960. doi: 10.1080/14656566.2018.1483339. Expert Opin Pharmacother. 2018. PMID: 29991320 Review.
Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.
Pallisgaard JL, Brooks MM, Chaitman BR, Boothroyd DB, Perez M, Hlatky MA; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Pallisgaard JL, et al. Am J Med. 2018 Jul;131(7):805-812. doi: 10.1016/j.amjmed.2018.02.026. Epub 2018 Mar 23. Am J Med. 2018. PMID: 29581079 Clinical Trial.
11,238 results
Jump to page
Feedback